{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T10:14:40Z","timestamp":1784542480028,"version":"3.55.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T00:00:00Z","timestamp":1699920000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T00:00:00Z","timestamp":1699920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["C38317\/A24043"],"award-info":[{"award-number":["C38317\/A24043"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To assess the effects of contemporary treatment of ductal carcinoma in situ (DCIS) on the risk of developing an ipsilateral invasive breast cancer (iIBC) in the Dutch female population.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Clinical data was obtained from the Netherlands Cancer Registry (NCR), a nationwide registry of all primary malignancies in the Netherlands integrated with the data from PALGA, the Dutch nationwide network and registry of histo- and cytopathology in the Netherlands, on all women in the Netherlands treated for primary DCIS from 2005 to 2015, resulting in a population-based cohort of 14.419 women. Cumulative iIBC incidence was assessed and associations of DCIS treatment type with subsequent iIBC risk were evaluated by multivariable Cox regression analyses.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Ten years after DCIS diagnosis, the cumulative incidence of iIBC was 3.1% (95% CI: 2.6\u20133.5%) in patients treated by breast conserving surgery (BCS) plus radiotherapy (RT), 7.1% (95% CI: 5.5\u20139.1) in patients treated by BCS alone, and 1.6% (95% CI: 1.3\u20132.1) in patients treated by mastectomy. BCS was associated with a significantly higher risk for iIBC compared to BCS\u2009+\u2009RT during the first 5 years after treatment (HR 2.80, 95% CI: 1.91\u20134.10%). After 5 years of follow-up, the iIBC risk declined in the BCS alone group but remained higher than the iIBC risk in the BCS\u2009+\u2009RT group (HR 1.73, 95% CI: 1.15\u20132.61).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Although absolute risks of iIBC were low in patients treated for DCIS with either BCS or BCS\u2009+\u2009RT, risks remained higher in the BCS alone group compared to patients treated with BCS\u2009+\u2009RT for at least 10 years after DCIS diagnosis.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10549-023-07168-8","type":"journal-article","created":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T17:02:44Z","timestamp":1699981364000},"page":"61-68","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The effects of contemporary treatment of DCIS on the risk of developing an ipsilateral invasive Breast cancer (iIBC) in the Dutch population"],"prefix":"10.1007","volume":"204","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5535-1703","authenticated-orcid":false,"given":"Sena","family":"Alaeikhanehshir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9e S.J.M.","family":"Schmitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra W.","family":"van den Belt-Dusebout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederieke H.","family":"van Duijnhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Verschuur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maartje","family":"van Seijen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schaapveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther H.","family":"Lips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelle","family":"Wesseling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"and Grand Challenge PRECISION Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,14]]},"reference":[{"key":"7168_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/bcr629","author":"MJ Van de Vijver","year":"2003","unstructured":"Van de Vijver MJ, Peterse H (2003) The diagnosis and management of pre-invasive breast Disease: pathological diagnosis \u2013 problems with existing classifications. Breast Cancer Res. https:\/\/doi.org\/10.1186\/bcr629","journal-title":"Breast Cancer Res"},{"key":"7168_CR2","doi-asserted-by":"publisher","unstructured":"Erbas B, Provenzano E, Armes J, Gertig D (May 2006) The natural history of ductal carcinoma in situ of the breast: a review. Breast Cancer Res Treat 97(2):135\u2013144. https:\/\/doi.org\/10.1007\/s10549-005-9101-z","DOI":"10.1007\/s10549-005-9101-z"},{"key":"7168_CR3","doi-asserted-by":"publisher","unstructured":"Ryser MD, Worni M, Turner EL, Marks JR, Durrett R, Hwang ES (May 2016) Outcomes of Active Surveillance for Ductal Carcinoma in situ: a computational risk analysis. \u201d J Natl Cancer Inst 108(5):djv372. https:\/\/doi.org\/10.1093\/jnci\/djv372","DOI":"10.1093\/jnci\/djv372"},{"issue":"1","key":"7168_CR4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA Cancer J Clin 69(1):7\u201334. https:\/\/doi.org\/10.3322\/caac.21551","journal-title":"CA Cancer J Clin"},{"key":"7168_CR5","unstructured":"Kankerbestrijding KWF (2016) \u201cIncidentie- en overlevingscijfers: Nederlandse Kankerregistratie,\u201d februari 2016. https:\/\/www.kwf.nl\/kanker\/borstkanker"},{"key":"7168_CR6","unstructured":"\u201cCancer Research UK (2017) \u201d 2017"},{"key":"7168_CR7","doi-asserted-by":"publisher","unstructured":"Bijker N, Donker M, Wesseling J, den Heeten GJ, Rutgers EJT (Mar. 2013) Is DCIS Breast Cancer, and how do I treat it? Curr Treat Options Oncol 14(1):75\u201387. https:\/\/doi.org\/10.1007\/s11864-012-0217-1","DOI":"10.1007\/s11864-012-0217-1"},{"key":"7168_CR8","doi-asserted-by":"publisher","unstructured":"Gierisch JM et al (2014) \u201cPrioritization of research addressing management strategies for ductal carcinoma in situ.,\u201d Ann. Intern. Med, vol.\u00a0160, no. 7, pp.\u00a0484\u201391, https:\/\/doi.org\/10.7326\/M13-2548","DOI":"10.7326\/M13-2548"},{"key":"7168_CR9","doi-asserted-by":"publisher","unstructured":"van Seijen M et al (Aug. 2019) Ductal carcinoma in situ: to treat or not to treat, that is the question. Br J Cancer 121(4):285\u2013292. https:\/\/doi.org\/10.1038\/s41416-019-0478-6","DOI":"10.1038\/s41416-019-0478-6"},{"key":"7168_CR10","doi-asserted-by":"publisher","unstructured":"Bleyer A, Welch HG (2012) \u201cEffect of three decades of screening mammography on breast-cancer incidence.,\u201d N. Engl. J. Med, vol.\u00a0367, no. 21, pp.\u00a01998\u20132005, Nov. https:\/\/doi.org\/10.1056\/NEJMoa1206809","DOI":"10.1056\/NEJMoa1206809"},{"issue":"15","key":"7168_CR11","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1056\/NEJMoa1600249","volume":"375","author":"BS Kramer","year":"2016","unstructured":"Kramer BS, Welch HG, Prorok PC, O\u2019Malley AJ, Kramer BS (2016) Breast-Cancer Tumor size, overdiagnosis, and Mammography Screening effectiveness. N Engl J Med 375(15):1438\u20131447. https:\/\/doi.org\/10.1056\/NEJMoa1600249","journal-title":"N Engl J Med"},{"key":"7168_CR12","doi-asserted-by":"publisher","unstructured":"Ruddy KJ et al (2013) \u201cLong-Term Risk Perceptions of Women With Ductal Carcinoma In Situ,\u201d Oncologist, vol.\u00a018, no. 4, pp.\u00a0362\u2013368, https:\/\/doi.org\/10.1634\/theoncologist.2012-0376","DOI":"10.1634\/theoncologist.2012-0376"},{"key":"7168_CR13","doi-asserted-by":"publisher","unstructured":"Narod SA, Iqbal J, Giannakeas V, Sopik V, Sun P (2015) \u201cBreast Cancer Mortality After a Diagnosis of Ductal Carcinoma In Situ.,\u201d JAMA Oncol, vol.\u00a01, no. 7, pp.\u00a0888\u201396, Oct. https:\/\/doi.org\/10.1001\/jamaoncol.2015.2510","DOI":"10.1001\/jamaoncol.2015.2510"},{"issue":"3","key":"7168_CR14","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s10549-016-3973-y","volume":"159","author":"LE Elshof","year":"2016","unstructured":"Elshof LE, Schaapveld M, Schmidt MK, Rutgers EJ, van Leeuwen FE, Wesseling J (2016) Subsequent risk of ipsilateral and contralateral invasive Breast cancer after treatment for ductal carcinoma in situ: incidence and the effect of radiotherapy in a population-based cohort of 10,090 women. Breast Cancer Res Treat 159(3):553\u2013563. https:\/\/doi.org\/10.1007\/s10549-016-3973-y","journal-title":"Breast Cancer Res Treat"},{"key":"7168_CR15","doi-asserted-by":"publisher","unstructured":"van Seijen M et al (2021) \u201cLong-term risk of subsequent ipsilateral lesions after surgery with or without radiotherapy for ductal carcinoma in situ of the breast.,\u201d Br. J. Cancer, vol.\u00a0125, no. 10, pp.\u00a01443\u20131449, https:\/\/doi.org\/10.1038\/s41416-021-01496-6","DOI":"10.1038\/s41416-021-01496-6"},{"key":"7168_CR16","doi-asserted-by":"publisher","unstructured":"Subhedar P, Olcese C, Patil S, Morrow M, Van Zee KJ (2015) \u201cDecreasing Recurrence Rates for Ductal Carcinoma In Situ: Analysis of 2996 Women Treated with Breast-Conserving Surgery Over 30 Years.,\u201d Ann. Surg. Oncol, vol.\u00a022, no. 10, pp.\u00a03273\u201381, Oct. https:\/\/doi.org\/10.1245\/s10434-015-4740-8","DOI":"10.1245\/s10434-015-4740-8"},{"key":"7168_CR17","doi-asserted-by":"publisher","unstructured":"Halasz LM et al (2012) \u201cImproved outcomes of breast-conserving therapy for patients with ductal carcinoma in situ.,\u201d Int. J. Radiat. Oncol. Biol. Phys, vol.\u00a082, no. 4, pp. e581-6, https:\/\/doi.org\/10.1016\/j.ijrobp.2011.08.015","DOI":"10.1016\/j.ijrobp.2011.08.015"},{"key":"7168_CR18","volume-title":"Cancer incidence in five continents","year":"2013","unstructured":"Forman FJ, Bray D, Brewster F, Gombe Mbalawa DH, Kohler C, Pi\u00f1eros B, Steliarova-Foucher M E, (eds) (2013) Cancer incidence in five continents, 10th edn. IARC Scientific Publications, Lyon","edition":"10"},{"issue":"1","key":"7168_CR19","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1155\/2007\/971816","volume":"29","author":"M Casparie","year":"2007","unstructured":"Casparie M et al (2007) Pathology databanking and biobanking in the Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive. \u201d Cell Oncol 29(1):19\u201324. https:\/\/doi.org\/10.1155\/2007\/971816","journal-title":"\u201d Cell Oncol"},{"key":"7168_CR20","doi-asserted-by":"crossref","unstructured":"Fine JP, Gray RJ, Fine JP, Gray RJ (1999) \u201cA Proportional Hazards Model for the Subdistribution of a Competing Risk Stable URL: http:\/\/www.jstor.org\/stable\/2670170 All use subject to http:\/\/about.jstor.org\/terms A Proportional Hazards Model for the Subdistribution of a Competing Risk,\u201d J. Am. Stat. Assoc, vol.\u00a094, no. 446, pp.\u00a0496\u2013509, [Online]. Available: http:\/\/www.jstor.org\/stable\/2670170","DOI":"10.1080\/01621459.1999.10474144"},{"key":"7168_CR21","unstructured":"\u201cDutch breast cancer guideline version 2.0\u201d (2020) https:\/\/www.oncoline.nl\/borstkanker"},{"key":"7168_CR22","doi-asserted-by":"publisher","unstructured":"Luiten JD et al (May 2021) Patterns of treatment and outcome of ductal carcinoma in situ in the Netherlands. \u201d Breast Cancer Res Treat 187(1):245\u2013254. https:\/\/doi.org\/10.1007\/s10549-020-06055-w","DOI":"10.1007\/s10549-020-06055-w"},{"key":"7168_CR23","doi-asserted-by":"publisher","unstructured":"Collins LC et al (2013) \u201cRisk factors for non-invasive and invasive local recurrence in patients with ductal carcinoma in situ.,\u201d Breast Cancer Res. Treat, vol.\u00a0139, no. 2, pp.\u00a0453\u201360, https:\/\/doi.org\/10.1007\/s10549-013-2539-5","DOI":"10.1007\/s10549-013-2539-5"},{"key":"7168_CR24","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1093\/jnci\/djg097","volume":"95","author":"K Kerlikowske","year":"2003","unstructured":"Kerlikowske K (2003) Characteristics Associated with recurrence among women with Ductal Carcinoma in situ treated by Lumpectomy. CancerSpectrum Knowl Environ 95:1692\u20131702. https:\/\/doi.org\/10.1093\/jnci\/djg097","journal-title":"CancerSpectrum Knowl Environ"},{"key":"7168_CR25","doi-asserted-by":"publisher","unstructured":"Hwang ES et al (Mar. 2019) The COMET (comparison of Operative versus Monitoring and Endocrine Therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS). BMJ Open 9(3):e026797. https:\/\/doi.org\/10.1136\/bmjopen-2018-026797","DOI":"10.1136\/bmjopen-2018-026797"},{"key":"7168_CR26","doi-asserted-by":"publisher","unstructured":"Francis A et al (2015) \u201cAddressing overtreatment of screen detected DCIS; the LORIS trial,\u201d Eur. J. Cancer, vol.\u00a051, no. 16, pp.\u00a02296\u20132303, https:\/\/doi.org\/10.1016\/j.ejca.2015.07.017","DOI":"10.1016\/j.ejca.2015.07.017"},{"key":"7168_CR27","doi-asserted-by":"publisher","unstructured":"Elshof LE et al (2015) \u201cFeasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ - The LORD study.,\u201d Eur. J. Cancer, vol.\u00a051, no. 12, pp.\u00a01497\u2013510, https:\/\/doi.org\/10.1016\/j.ejca.2015.05.008","DOI":"10.1016\/j.ejca.2015.05.008"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-023-07168-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-023-07168-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-023-07168-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T11:22:01Z","timestamp":1706008921000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-023-07168-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,14]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["7168"],"URL":"https:\/\/doi.org\/10.1007\/s10549-023-07168-8","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,14]]},"assertion":[{"value":"7 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the review boards of the Netherlands Cancer Institute, Netherlands Cancer Registry and PALGA. The study used only unidentifiable patient information, and no informed consent was required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}